TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will present data from its Phase Ia trial of crinobulin at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 29 to June 2, 2009 in Orlando, Florida. Crinobulin is EpiCept’s novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.
